Yabao Pharmaceutical Group (600351.SH): SY-005 Project Receives Clinical Trial Approval for New Indication

Stock News

2025/08/25

Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration for an additional indication of SY-005 injection. The approval permits clinical trials of SY-005 injection for treating post-operative neurological dysfunction following brain glioma surgery.

SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis treatment in November 2018. The sepsis indication is currently in Phase II clinical trials. The newly approved indication for SY-005 injection is post-operative neurological dysfunction after brain glioma surgery.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1112421026"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112421026\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112421026?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112421026","market":"us","top_or_hot":-1,"title":"Yabao Pharmaceutical Group (600351.SH): SY-005 Project Receives Clinical Trial Approval for New Indication","media":"Stock News","content":"<p>Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration for an additional indication of SY-005 injection. The approval permits clinical trials of SY-005 injection for treating post-operative neurological dysfunction following brain glioma surgery.</p>\n<p>SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis treatment in November 2018. The sepsis indication is currently in Phase II clinical trials. The newly approved indication for SY-005 injection is post-operative neurological dysfunction after brain glioma surgery.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yabao Pharmaceutical Group (600351.SH): SY-005 Project Receives Clinical Trial Approval for New Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYabao Pharmaceutical Group (600351.SH): SY-005 Project Receives Clinical Trial Approval for New Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-25 15:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration for an additional indication of SY-005 injection. The approval permits clinical trials of SY-005 injection for treating post-operative neurological dysfunction following brain glioma surgery.</p>\n<p>SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis treatment in November 2018. The sepsis indication is currently in Phase II clinical trials. The newly approved indication for SY-005 injection is post-operative neurological dysfunction after brain glioma surgery.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4503","symbol_name":"景林资产持仓","start_time":0,"source_url":"","article_id":"1112421026","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112421026","pubTimestamp":1756107385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the \"Clinical Trial Approval Notice\" issued by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600351":"亚宝药业","BK4503":"景林资产持仓","SY":"新氧","BK0028":"国家队","BK4077":"互动媒体与服务","BK0239":"医药制造","BK0201":"可转债","BK0096":"民营医院","BK4563":"昨日强势股","BK0077":"质押式回购"},"translate_title":"亚宝药业集团（600351.SH）：SY-005项目获新适应症临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600351":1,"SY":1},"content_text":"Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration for an additional indication of SY-005 injection. The approval permits clinical trials of SY-005 injection for treating post-operative neurological dysfunction following brain glioma surgery.\nSY-005 is an innovative recombinant protein that received clinical trial approval for sepsis treatment in November 2018. The sepsis indication is currently in Phase II clinical trials. The newly approved indication for SY-005 injection is post-operative neurological dysfunction after brain glioma surgery.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}